Pain ReliefTrials

New research project examines CBD for pain

Does CBD help with pain

The National Institute for Health and Care Excellence has no guidelines that are relevant to cannabinoid-based medical treatments. Basically, this means that those who are taking such medicines are operating outside the law.

There are now moves to generate a change in the country especially in relation to the MHRA. Dr Saoirse O’Sullivan is spearheading the research examining the potential of cannabinoid-based medicine users in the UK.

CBD-usage data desperately needed

What’s needed for change to take place is concrete data on the state of CBD usage in the United Kingdom. The report intends to focus on what CBD is and how patients can use, the most up-to-date science on the matter, effectiveness of various dosages, variability in responses, as well as side effects.

Also Read:  What is CBD oil & what can it do for you?

All of these are of keen interest to a growing consumer-based who want to see if cannabinoid-based medications could be an answer to their ailments. Dr O'Sullivan's research interests are primarily in investigating the role of the endocannabinoid system in the vasculature in health.

Cannabinoid wisdom from CBD Expo’s ExCel keynote speaker

Dr Saoirse O’Sullivan, who is Associate Professor of the Faculty of Medicine and Health Sciences at the University of Nottingham, will be giving a talk at the UK’s very first medicinal cannabis and cannabinoid tradeshow, Europe CBD Expo in Excel London at the start of July. This expo will gather together researchers, scientists, investors, and many more to share their knowledge of the flourishing medicinal cannabis industry in Europe.

Her talk, titled Endocannabinoid System (ECS) with Reference to Diabetes & Obesity, will surely mention many of the benefits that could be gained were there greater cannabinoid access for patients. Dr O'Sullivan's research interests are primarily in investigating the role of the endocannabinoid system in the vasculature in health. She has 15 years of cannabinoid wisdom.

Also Read:  The Extract announces new media partnership with The CBD Show

cannabidiol UK

The report that Dr O’Sullivan is leading will also focus on various legislative measures that could and should be taken in the United Kingdom. As we said at the moment the use of cannabinoid-based medications is operating in a grey area outside the law.

This puts doctors, pharmacists, and other health practitioners in an uneasy position with regards to how they can help their patients. The last thing any sort of medical treatment needs is a grey area within the UK law.

Also Read:  Start Your Own Business With CBD White Labeling

Patients need greater access to medication

Hopefully, with a report such as this it will be easier to lay the case before the media, the public, and the policy stakeholders, and from there allow patients greater access to these medications.

Throughout Europe, there is a degree of difference in how each state operates from partial legalisation to outright banning. There needs to be consensus and thus an outline for the NHS to follow for patients to be satisfied with their pain management in future.

Jon Cosgrave

Jon is a content writer and copywriter. When not grappling with words, he grapples at jiu-jitsu. His fingers are in constant agony.

Related Articles

Leave a Reply

Back to top button